Chronic Kidney Disease Screening Practice Among High-Risk Patients During Follow-Up in Sub-Saharan Africa: A Systematic Review
Health Services Insights · 2026-07 · 19
DOI: 10.1177/11786329261468554 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Health Services Insights, online erschienen am 13.07.2026. Verfasst von Habtamu Abera Areri und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Surgical Nursing, School of Nursing and Midwifery, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Screening for Chronic Kidney Disease (CKD) for high-risk patients is essential to provide early detection, management, and delayed progression. In Sub-Saharan Africa (SSA), CKD screening remains variable and inadequate. Therefore, the review question was: what is the current practice of screening for CKD in high-risk patients (hypertension and diabetes) attending chronic care follow-up visits in SSA?
Methods
The systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) 2020 guidelines. The review included studies published from 2010 to August 2025. Inclusion criteria included screening practices or early detection of chronic kidney diseases among high-risk patients during routine care in SSA. The review followed the JBI Condition, Context, and Population (CoCoPop) protocol. Two independent reviewers screened, appraised, and extracted data using the standardized JBI SUMARI data extraction form. Narrative synthesis of the findings was carried out to understand CKD screening practice in SSA.
Results
Out of 856 records identified, twelve studies from SSA focused on high-risk patients screened for CKD who met criteria and were included. Serum creatinine was the most common method used to screen CKD during routine follow-up of high-risk patients, followed by albuminuria and estimated glomerular filtration rate(eGFR). The prevalence of CKD screening during routine care varies from 8.4% to 38.5%. Older age, being a female, duration of diabetes and/or hypertension, and co-existence of hypertension and diabetes were identified as factors associated with CKD screening practice. Conclusion and recommendations Routine follow-up of high-risk patients demonstrated that CKD screening was effective in early patient identification. Most of the included studies relied on one-time screening, which may not accurately represent the true prevalence; therefore, confirmatory CKD screening should be conducted. Finally, healthcare providers should prioritize older age, female gender, duration of the high-risk conditions, and concomitance of hypertension and diabetes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Surgical Nursing, School of Nursing and Midwifery, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
- Department of Nephrology, School of Medicine, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
- Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, USA.
ORCID-Profile: Habtamu Abera Areri
Zitieren
APA
Areri, H. A., Mengistu, Y. T., & Gary, R. (2026). Chronic Kidney Disease Screening Practice Among High-Risk Patients During Follow-Up in Sub-Saharan Africa: A Systematic Review. Health Services Insights, 19. https://doi.org/10.1177/11786329261468554
Vancouver
Areri HA, Mengistu YT, Gary R. Chronic Kidney Disease Screening Practice Among High-Risk Patients During Follow-Up in Sub-Saharan Africa: A Systematic Review. Health Services Insights. 2026;19. doi:10.1177/11786329261468554
BibTeX
@article{Areri2026,
author = {Areri, Habtamu Abera and Mengistu, Yewondwossen Tadesse and Gary, Rebecca},
title = {Chronic Kidney Disease Screening Practice Among High-Risk Patients During Follow-Up in Sub-Saharan Africa: A Systematic Review},
journal = {Health Services Insights},
year = {2026},
volume = {19},
doi = {10.1177/11786329261468554}
}
EUVIMED